bortezomib + temsirolimus

A two-drug cancer regimen combining the proteasome inhibitor bortezomib and the mTOR inhibitor temsirolimus. Bortezomib reversibly inhibits the 26S proteasome, disrupting degradation of ubiquitinated proteins, causing cell cycle arrest and apoptosis in malignant cells. Temsirolimus inhibits the mTOR pathway (primarily mTORC1), reducing protein synthesis, cell proliferation, and survival signaling. The combination has been clinically tested in relapsed or refractory multiple myeloma and B‑cell non‑Hodgkin lymphoma, showing activity with manageable toxicity in early-phase studies. In trials, both agents were administered intravenously on a weekly schedule within 35‑day cycles without routine steroids in the myeloma study.

Other names

Velcade + Toriselbortezomib plus temsirolimustemsirolimus plus bortezomib